Short Interest of Life Sciences Companies at a High Point.
Interesting list of name for the incoming CPI..
$Novavax(NVAX.US)$ $SPDR S&P Biotech ETF(XBI.US)$ $S&P 500 Index(.SPX.US)$

$Sunshine Biopharma(SBFM.US)$ $SPDR S&P Biotech ETF(XBI.US)$ Squad is Coming

$SPDR S&P Biotech ETF(XBI.US)$ PSYCHEDELICS
Time to say hello to $Clearmind Medicine(CMND.US)$

No megadeals in biotech so far this yr, but on track for record amount >$1 bil deals,
2 biggest deals this yr:
$Vertex Pharmaceuticals(VRTX.US)$ paid $4.9 bil for $Alpine Immune(ALPN.US)$
$Gilead Sciences(GILD.US)$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...

The FDA PDUFA Calendar is a chronological calendar of PDUFA target dates as well as Advisory meetings (ADCOMM). PDUFA target dates are dates by which the FDA aims to deliver their decision regarding an NDA or BLA filing. These decisions can however come before the PDUFA target date.
$Pfizer(PFE.US)$ $Dynavax Technologies(DVAX.US)$ $Sandstorm Gold(SAND.US)$ $Bristol-Myers Squibb(BMY.US)$ $SPDR S&P Biotech ETF(XBI.US)$

$SPDR S&P Biotech ETF(XBI.US)$
Assumptions: Overall market is stable and not turning into bear market; US economy no recession;  Better to start rate cut in 2024.
$Nasdaq Composite Index(.IXIC.US)$ $S&P 500 Index(.SPX.US)$

$SPDR S&P Biotech ETF(XBI.US)$ $iShares Biotechnology ETF(IBB.US)$
M&A in Q1 alone totaled 12 deals for $19.2 bil which is close to the 10 deals for $21.9 bil in all the 1H of 2023...
But one big caveat of this chart, it doesn't include $Pfizer(PFE.US)$ 's $43 bil deal for $SGEN announced in Mar 2023 but didn't close until Dec bc of an FTC challenge,
The biggest biotech M&A deal so far this yr was $Gilead Sciences(GILD.US)$ 's $4.3 b...

$SPDR S&P Biotech ETF(XBI.US)$ $iShares Biotechnology ETF(IBB.US)$
Observations from $VINC (-60% AH):
1- When companies tout "strong safety profile", often means efficacy is a big fat zero
2- Phrases like "dose dependent clinical activity" set the bar low
3- "Promising" doesn't necessarily refer to SP
Stay skeptical, my friends.

$SPDR S&P Biotech ETF(XBI.US)$ $iShares Biotechnology ETF(IBB.US)$
Mike on biotech's correlation with interest rates:
"Biotech is essentially a call option on $iShares 20+ Year Treasury Bond ETF(TLT.US)$
Biotech bulls need inflation and rates to move lower for resumption of a real bull market.
XBI is likely to remain range-bound - or worse - until inflation convincingly moves lower.
Hopefully we can grind out reasonable returns in the meantime by buying the right stocks, but we will b...

$SPDR S&P Biotech ETF(XBI.US)$
$Merck & Co(MRK.US)$ x $Immunovant(IMVT.US)$
$Eli Lilly and Co(LLY.US)$ x $Cytokinetics(CYTK.US)$ (and soon)
$Regeneron Pharmaceuticals(REGN.US)$ x $Apellis Pharmaceuticals(APLS.US)$ (panache & brash)
$Gilead Sciences(GILD.US)$ x % $Madrigal Pharmaceuticals(MDGL.US)$ (liver king)
$Bristol-Myers Squibb(BMY.US)$ x $Iovance Biotherapeutics(IOVA.US)$ (cell Tx boost needed)
$Eli Lilly and Co(LLY.US)$ x $Merus(MRUS.US)$ (partner n...